Exposición radiológica de los trabajadores y el público en la primera fase del ensayo clínico del Nimotuzumab marcado con para el tratamiento de tumores cerebrales en Cuba

abstract the first phase of the clinical trial using the humanized monoclonal antibody h-r3 (nimotuzumab) labelled with , for radioimmunotherapy of brain malignant was performed during the period 2002-2005 in cuba. the aim of this work was to analyze data from the radiological surveillance of this research compared to initially estimated doses. these latter were calculated for each activity level, operation and total quantity of patients, considering the radioactive decay of and taking into account that only one person carries out all of the operations. it was demonstrated that the radiation risk of the practice is acceptable. the conservative hypotheses for dose assessment and the compliance with established safety procedures during this trial showed that the measured exposure was lower than that estimated. this paper is a reference useful to introduce and develop the rit in cuba.